Paul Tudor Jones Terns Pharmaceuticals, Inc. Transaction History
Tudor Investment Corp Et Al
- $26.8 Billion
- Q3 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 10,263 shares of TERN stock, worth $59,525. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,263
Previous 15,753
34.85%
Holding current value
$59,525
Previous $107,000
20.56%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding TERN
# of Institutions
167Shares Held
78.3MCall Options Held
580KPut Options Held
454K-
Orbimed Advisors LLC San Diego, CA7.56MShares$43.9 Million1.49% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$40 Million8.42% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.22MShares$36.1 Million4.41% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.58MShares$32.3 Million1.71% of portfolio
-
Black Rock Inc. New York, NY4.12MShares$23.9 Million0.0% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $218M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...